VAXIMM

24 articles about VAXIMM

• NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

  3/8/2022

  NEC OncoImmunity announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM’s neoantigen program assets.

• 

  BioSpace Movers & Shakers, July 10

  7/10/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

  11/12/2019

  Clinical trial collaboration agreement leverages NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology

• VAXIMM Announces Presentations at Upcoming Industry and Scientific Event

  9/12/2019

  VAXIMM AG announced that the Company will participate in several events around the globe in the coming months.

• VAXIMM Announces Presentations at ASCO 2019 and Other Upcoming Industry and Scientific Events

  4/18/2019

  VAXIMM AG announced that the Company will present an abstract about the design of its ongoing trial in patients with glioblastoma with VXM01 oral T-cell immunotherapy in combination with the anti-PD-L1 checkpoint inhibitor avelumab at the 2019 American Society of Clinical Oncology Annual Meeting.

• VAXIMM Announces Presentations at Upcoming Industry and Scientific Events on October and November 2018

  9/28/2018

  VAXIMM AG today announced that the Company will participate in several upcoming events in the fourth quarter of 2018.

• VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

  9/20/2018

  CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan

• VAXIMM AG Announces Presentations at Upcoming Industry and Scientific Events

  1/18/2018

  VAXIMM today announced that the Company will participate in several upcoming events in the first quarter of 2018.

• VAXIMM Announces Data From Phase I Trial In Glioblastoma With Oral T-Cell Immunotherapy VXM01 To Be Presented At ASCO 2017 Annual Meeting

  5/18/2017

• VAXIMM Announces Collaboration With Merck KGaA, Darmstadt, Germany, And Pfizer To Evaluate Combination Of VXM01 With Avelumab In Glioblastoma And Colorectal Cancer In Phase I/II Clinical Studies

  5/9/2017

• VAXIMM Announces Presentations At Upcoming Industry And Scientific Events

  5/3/2017

• VAXIMM To Present Preclinical Data On Three Novel Oral T-Cell Immunotherapies At AACR Annual Meeting 2017

  3/30/2017

• VAXIMM Presents Preclinical Data On Three Novel Oral T-Cell Cancer Immunotherapies At EORTC-NCI-AACR Symposium

  12/1/2016

• VAXIMM Appoints Dr. Matthias Schroff As Chief Executive Officer

  9/1/2016

• VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01

  7/12/2016

• ASCO2016: VAXIMM Presents Data From Phase I Trial In Pancreatic Cancer With Oral T-Cell Immunotherapy VXM01 At ASCO 2016 Annual Meeting

  6/6/2016

• VAXIMM Initiates Phase 2a Study In Advanced Colorectal Cancer With Oral T-Cell Vaccine VXM01

  5/4/2016

• VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial

  12/4/2014

• VAXIMM Study Meets Endpoints in Phase 1/2

  2/7/2013

• VAXIMM Completes Enrollment of First Oral Cancer Vaccine Trial

  10/22/2012